About InVitae (NYSE:NVTA)
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Industry, Sector and Symbol
Industry Bio Diagnostics & Testing
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$25.05 million
Price / Sales17.86
Price / CashN/A
Book Value$2.41 per share
Price / Book3.51
Return on Equity-115.25%
Return on Assets-67.79%
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) announced its earnings results on Monday, August, 8th. The medical research company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.01. The medical research company had revenue of $5.60 million for the quarter, compared to analysts' expectations of $5.81 million. InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. The business's revenue was up 211.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) earnings per share. View InVitae's Earnings History.
When will InVitae make its next earnings announcement?
Where is InVitae's stock going? Where will InVitae's stock price be in 2017?
3 analysts have issued 12-month price targets for InVitae's shares. Their forecasts range from $12.00 to $16.00. On average, they expect InVitae's stock price to reach $14.33 in the next year. View Analyst Ratings for InVitae.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Luminex (LMNX), BioTelemetry (BEAT), AxoGen (AXGN), Assembly Biosciences (ASMB), Quality Systems (QSII), Audentes Therapeutics (BOLD), Eagle Pharmaceuticals (EGRX), Amphastar Pharmaceuticals (AMPH), Retrophin (RTRX), Intersect ENT (XENT), Adamas Pharmaceuticals (ADMS), ImmunoGen (IMGN), ARGENX (ARGX), ANI Pharmaceuticals (ANIP), Pharming Group (PHGUF), Rhythm Pharmaceuticals (RYTM), Almost Family (AFAM) and CytomX Therapeutics (CTMX).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Randal W. Scott Ph.D., Executive Chairman of the Board (Age 59)
- Sean E. George Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 43)
- Shelly D Guyer, Chief Financial Officer (Age 56)
- Lee Bendekgey J.D., Chief Operating Officer, General Counsel, Secretary (Age 59)
- Robert L. Nussbaum M.D., Chief Medical Officer (Age 67)
- Christine M. Gorjanc, Lead Independent Director (Age 60)
- Eric Aguiar M.D., Independent Director (Age 55)
- Geoffrey S. Crouse, Independent Director (Age 46)
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who owns InVitae stock?
InVitae's stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (3.75%), Orbimed Advisors LLC (3.02%), Bank of New York Mellon Corp (0.35%), Allianz Asset Management GmbH (0.34%), Schwab Charles Investment Management Inc. (0.32%) and Private Wealth Partners LLC (0.20%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Lisa Alderson, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George and Thomas Brida. View Institutional Ownership Trends for InVitae.
Who sold InVitae stock? Who is selling InVitae stock?
InVitae's stock was sold by a variety of institutional investors in the last quarter, including Cubist Systematic Strategies LLC and California State Teachers Retirement System. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum and Thomas Brida. View Insider Buying and Selling for InVitae.
Who bought InVitae stock? Who is buying InVitae stock?
InVitae's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Orbimed Advisors LLC, Private Wealth Partners LLC, Allianz Asset Management GmbH, Schwab Charles Investment Management Inc., Fox Run Management L.L.C., OxFORD Asset Management LLP and CAPROCK Group Inc.. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse, Randal W Scott and Sean E George. View Insider Buying and Selling for InVitae.
How do I buy InVitae stock?
Shares of InVitae can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of InVitae stock can currently be purchased for approximately $8.45.
How big of a company is InVitae?
InVitae has a market capitalization of $457.45 million and generates $25.05 million in revenue each year. The medical research company earns $-100,250,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. InVitae employs 332 workers across the globe.
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NVTA)MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
InVitae (NYSE:NVTA) Earnings History and Estimates Chart
InVitae (NYSE NVTA) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||6/30/2017||($0.64)||($0.66)||$13.31 million||$14.34 million||View||Listen|
|5/9/2017||Q1 2017||($0.68)||($0.64)||$10.90 million||$10.34 million||View||Listen|
|2/13/2017||Q416||($0.73)||($0.69)||$8.82 million||$9.20 million||View||N/A|
|11/7/2016||Q316||($0.72)||($0.77)||$7.50 million||$6.30 million||View||Listen|
|8/8/2016||Q216||($0.76)||($0.77)||$5.81 million||$5.60 million||View||N/A|
|5/9/2016||Q116||($0.76)||($0.80)||$4.38 million||$4.00 million||View||N/A|
|2/9/2016||Q415||($0.72)||($0.76)||$2.92 million||$3.20 million||View||N/A|
|11/5/2015||Q315||($0.70)||($0.71)||$2.55 million||$2.19 million||View||N/A|
|8/6/2015||Q215||($0.55)||($0.76)||$1.67 million||$1.80 million||View||N/A|
|5/12/2015||Q115||($0.51)||($1.09)||$1.07 million||$1.23 million||View||Listen|
InVitae (NYSE:NVTA) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.45 EPS
Next Year EPS Consensus Estimate: $-1.7 EPS
Dividend History for InVitae (NYSE:NVTA)
No dividend announcements for this company have been tracked by MarketBeat.com
InVitae (NYSE NVTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 66.52%
InVitae (NYSE NVTA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/10/2017||Patty Dumond||VP||Sell||2,497||$10.00||$24,970.00|| |
|10/9/2017||Patty Dumond||VP||Sell||1,882||$10.00||$18,820.00|| |
|9/12/2017||Katherine Stueland||Insider||Sell||612||$9.40||$5,752.80|| |
|2/16/2017||Thomas Brida||General Counsel||Sell||766||$9.69||$7,422.54|| |
|2/15/2017||E Lee Bendekgey||CFO||Sell||2,098||$9.59||$20,119.82|| |
|2/15/2017||Patty Dumond||VP||Sell||1,264||$9.55||$12,071.20|| |
|2/15/2017||Robert L Nussbaum||Insider||Sell||1,686||$9.53||$16,067.58|| |
|2/15/2017||Thomas Brida||General Counsel||Sell||794||$9.54||$7,574.76|| |
|11/22/2016||Randal W Scott||Chairman||Buy||66,666||$6.00||$399,996.00|| |
|11/18/2016||Geoffrey Crouse||Director||Buy||15,000||$6.25||$93,750.00|| |
|11/17/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||733,333||$6.00||$4,399,998.00|| |
|9/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00|| |
|8/15/2016||Patty Dumond||VP||Sell||1,000||$8.81||$8,810.00|| |
|7/14/2016||Patty Dumond||VP||Sell||1,000||$8.79||$8,790.00|| |
|6/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00|| |
|5/17/2016||Patty Dumond||VP||Sell||3,221||$8.47||$27,281.87|| |
|4/14/2016||Patty Dumond||VP||Sell||1,000||$10.50||$10,500.00|| |
|2/22/2016||Lisa Alderson||Insider||Sell||7,500||$7.64||$57,300.00|| |
|2/11/2016||Sean E George||COO||Buy||16,950||$6.16||$104,412.00|| |
|2/18/2015||James E Flynn||Insider||Buy||175,000||$16.00||$2,800,000.00|| |
InVitae (NYSE NVTA) News Headlines
|InVitae Corp (NVTA) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - December 11 at 6:46 PM
|ETFs with exposure to Invitae Corp. : December 11, 2017|
finance.yahoo.com - December 11 at 4:41 PM
|InVitae Corp (NVTA) Expected to Announce Quarterly Sales of $25.87 Million|
www.americanbankingnews.com - December 11 at 2:56 PM
|Vermillion (VRML) & InVitae (NVTA) Critical Comparison|
www.americanbankingnews.com - December 10 at 3:30 PM
|InVitae Corp (NVTA) Expected to Announce Earnings of -$0.55 Per Share|
www.americanbankingnews.com - December 9 at 8:04 AM
|Financial Survey: Veracyte (VCYT) versus InVitae (NVTA)|
www.americanbankingnews.com - December 3 at 9:48 PM
|Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017|
finance.yahoo.com - November 30 at 11:01 AM
|Comparing Digiliti Money (DGLT) & InVitae (NVTA)|
www.americanbankingnews.com - November 29 at 9:44 PM
|Contrasting InVitae (NVTA) and CareDx (CDNA)|
www.americanbankingnews.com - November 27 at 10:10 AM
|Invitae Corporation (NVTA) Rating Lowered to Strong Sell at BidaskClub|
www.americanbankingnews.com - November 25 at 12:50 AM
|$25.87 Million in Sales Expected for Invitae Corporation (NVTA) This Quarter|
www.americanbankingnews.com - November 23 at 8:58 AM
|Critical Analysis: CareDx (CDNA) and Invitae Corporation (NVTA)|
www.americanbankingnews.com - November 22 at 1:23 PM
|-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter|
www.americanbankingnews.com - November 21 at 9:24 AM
|Lion Biotechnologies (IOVA) & Invitae Corporation (NVTA) Critical Review|
www.americanbankingnews.com - November 18 at 1:30 PM
|Invitae Corporation (NVTA) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - November 16 at 2:10 PM
|Invitae reports 1Q loss|
marketbeat.com - May 8 at 4:34 PM
|Invitae Expands Test Menu for Proactive Genetic Testing in Healthy Adults|
us.rd.yahoo.com - March 23 at 7:28 PM
|Invitae announces expansion of its genetic testing offering to include unique test for Spinal Muscular Atrophy (SMA) during the 2017 ACMG Annual Clinical Genetics Meeting|
us.rd.yahoo.com - March 22 at 9:10 AM
|INVITAE CORP Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 16 at 7:40 PM
|Get Ready: Biotech Is Ready To Break Out|
seekingalpha.com - February 28 at 10:35 AM
|18 Biggest Mid-Day Gainers For Tuesday | Benzinga - Benzinga|
www.benzinga.com - February 14 at 10:12 PM
|Q4 2016 Invitae Corp Earnings Release - Time Not Supplied|
biz.yahoo.com - February 13 at 9:39 AM
|Form 8-K Invitae Corp For: Jan 06 - StreetInsider.com - StreetInsider.com|
www.streetinsider.com - January 13 at 12:37 AM
|INVITAE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex|
biz.yahoo.com - January 9 at 7:38 PM
|7:01 am Invitae acquires privately owned AltaVoice; financial details not disclosed|
us.rd.yahoo.com - January 7 at 5:42 AM
|InVitae (NVTA) Says it Met Annual Volume Guidance, Sees Doubling in 2017 - StreetInsider.com|
www.streetinsider.com - January 6 at 7:39 PM
|INVITAE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition|
biz.yahoo.com - January 6 at 7:39 PM
|InVitae Execs Talk Genetics And Growth - Benzinga|
www.benzinga.com - December 18 at 7:12 PM
InVitae (NYSE:NVTA) SEC Filings
Park West Asset Management LLC (Filed by)
|Form SC 13G|
InVitae (NYSE:NVTA) Income Statement, Balance Sheet and Cash Flow Statement
InVitae (NYSE NVTA) Stock Chart for Tuesday, December, 12, 2017